Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835176 | 0.88 | NPY5R (0.51) | NPY5RCYP2C9CYP3A4 | |
| SCHEMBL6831681 | 0.87 | NPY5R (0.52) | NPY5RCYP11B2CYP11B1CYP19A1CYP3A4 | |
| SCHEMBL6835215 | 0.87 | NPY5R (0.53) | NPY5RCYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL6834619 | 0.84 | NPY5R (0.53) | NPY5RCYP11B2CYP11B1 | |
| SCHEMBL6836938 | 0.82 | NPY5R (0.48) | NPY5RCYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL6835181 | 0.82 | NPY5R (0.49) | NPY5RCYP11B2CYP19A1CYP2C9CYP3A4 | |
| SCHEMBL6836913 | 0.80 | NPY5R (0.55) | NPY5RPDE10A | |
| SCHEMBL6835192 | 0.74 | NPY5R (0.50) | NPY5RCYP11B2CYP19A1 | |
| SCHEMBL6834506 | 0.71 | NPY5R (0.48) | NPY5RCYP2C9 | |
| SCHEMBL7372635 | 0.71 | CYP11B2 (0.52) | CYP11B2CYP11B1CYP19A1CYP17A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-01-22 | — | — | US | claimed |
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | NPY5R 983/4885CYP11B2 51/4885CYP11B1 67/4885 |
| US-20040014753-A1 | Novel interleukin-1beta converting enzyme inhibitors | IL1B, IL1RN, IL1R1 | NPY5R 1700/4885CYP11B2 472/4885CYP11B1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.